# üéØ SAE BRCA VALIDATION: NEXT 10 DELIVERABLES

**Date**: 2025-01-29  
**Status**: üöß **IN PROGRESS** - Planning phase complete, execution ready  
**Context**: BRCA checkpoint validated (200 patients, 6,465 variants), ready for pathway mapping & validation  
**Mars Rules**: Minimal viable proof, 72-hour mindset, replace gene-level tests

---

## üéØ EXECUTIVE SUMMARY

**Current State**:
- ‚úÖ BRCA checkpoint validated (200 patients, 6,465 variants, SAE features extracted)
- ‚úÖ OV DDR pathway mapping identified (9 diamond features)
- ‚úÖ Manager plan reviewed (4 critical issues identified and corrected)
- ‚úÖ Execution strategy defined (parallel testing approach)
- ‚ö†Ô∏è **Recurrence labels missing** - Need to extract from TCGA-BRCA clinical data
- ‚ö†Ô∏è **Pathway mapping pending** - Need to test OV DDR transfer + BRCA-specific mapping
- ‚ö†Ô∏è **Validation pending** - Need to compare SAE vs Oncotype DX

**Goal**: Execute BRCA SAE validation to prove variant-level features beat Oncotype DX ($500M market)

---

## üìã THE 10 DELIVERABLES

### 1. **Extract BRCA Recurrence Labels** üî• **CRITICAL BLOCKER**

**Status**: ‚ö†Ô∏è **PENDING** - Required before any validation  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGHEST** - Blocks all downstream work

**What**: Extract recurrence outcomes from TCGA-BRCA clinical data

**Deliverable**:
- File: `scripts/sae/extract_brca_recurrence_labels.py`
- Output: `data/validation/sae_cohort/brca_recurrence_labels.json`
- Format:
  ```json
  {
    "TCGA-XX-XXXX": {
      "recurrence": true/false,
      "recurrence_free_survival_months": float,
      "vital_status": "alive"/"deceased",
      "dfs_status": "0:DiseaseFree"/"1:Recurred/Progressed"
    }
  }
  ```

**Key Corrections** (from manager plan review):
- ‚úÖ Use `DFS_STATUS` as primary field (not `new_tumor_event`)
- ‚úÖ Handle multiple field name variations (defensive)
- ‚úÖ Parse DFS_STATUS format: "0:DiseaseFree" vs "1:Recurred/Progressed"

**Success Criteria**:
- ‚úÖ 150+ patients with recurrence labels (out of 200)
- ‚úÖ Binary outcome: recurrence = True/False
- ‚úÖ Survival time data available
- ‚úÖ Matches BRCA checkpoint patient IDs

**Timeline**: 4 hours

---

### 2. **Verify DDR_bin Aggregation Method** üî• **CRITICAL**

**Status**: ‚ö†Ô∏è **PENDING** - Must resolve before OV DDR transfer test  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGHEST** - Affects all pathway scoring

**What**: Resolve discrepancy between code (max) and manuscript (mean) for DDR_bin

**Deliverable**:
- File: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/DDR_BIN_AGGREGATION_VERIFICATION.md`
- Investigation:
  - Check OV validation code: Which method was used?
  - Check manuscript: Which method is documented?
  - Check actual OV results: Which method produced AUROC 0.783?
- Decision:
  - Use same method as OV validation (for consistency)
  - Update documentation if needed
  - Document decision for BRCA validation

**Key Issue** (from manager plan review):
- Code uses: `max(max(diamond_features_per_variant))`
- Manuscript says: `mean(diamond_features)`
- Need to verify which was actually used for OV AUROC 0.783

**Success Criteria**:
- ‚úÖ Aggregation method verified (code vs manuscript)
- ‚úÖ Decision documented (which method to use for BRCA)
- ‚úÖ Consistency ensured (same method as OV)

**Timeline**: 2 hours

---

### 3. **Check OV DDR Feature Coverage in BRCA** ‚ö†Ô∏è **IMPORTANT**

**Status**: ‚ö†Ô∏è **PENDING** - Need to verify before OV DDR transfer test  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: ‚ö†Ô∏è **HIGH** - May require re-extraction if coverage low

**What**: Check how many BRCA variants have OV DDR features in top-64

**Deliverable**:
- File: `scripts/sae/check_ov_ddr_coverage_brca.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/ov_ddr_coverage_report.json`
- Metrics:
  - Mean coverage per patient (how many OV DDR features present)
  - Coverage per variant (how many variants have OV DDR features)
  - Missing feature analysis (which OV DDR features are missing)
- Decision:
  - If coverage ‚â• 50%: Proceed with OV DDR transfer test
  - If coverage < 50%: Re-extract full 32K for OV DDR indices only

**Key Issue** (from manager plan review):
- BRCA checkpoint has `top_features` (k=64), not full 32K
- OV DDR features may not be in top-64 for BRCA variants
- Missing features = 0.0, which may affect results

**Success Criteria**:
- ‚úÖ Coverage statistics computed
- ‚úÖ Decision made: Proceed or re-extract
- ‚úÖ If re-extract needed: Plan documented

**Timeline**: 2 hours

---

### 4. **Test OV DDR Transfer to BRCA** üî• **HIGH PRIORITY**

**Status**: ‚ö†Ô∏è **PENDING** - Depends on #1, #2, #3  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGH** - Core hypothesis test

**What**: Test if OV DDR diamond features predict BRCA recurrence

**Deliverable**:
- File: `scripts/sae/test_ov_ddr_transfer_to_brca.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/ov_ddr_transfer_results.json`
- Results:
  ```json
  {
    "ov_ddr_auroc": 0.68,
    "interpretation": "moderate",
    "next_action": "refine_brca_ddr",
    "feature_coverage": {...},
    "n_patients": 150,
    "decision": "Scenario B: Moderate transfer (0.60-0.69)"
  }
  ```

**Key Corrections** (from manager plan review):
- ‚úÖ Handle missing features (use 0.0 if not in top-64)
- ‚úÖ Use verified aggregation method (from #2)
- ‚úÖ Filter None outcomes
- ‚úÖ Add coverage stats to output

**Success Criteria**:
- ‚úÖ AUROC computed (OV DDR ‚Üí BRCA recurrence)
- ‚úÖ Interpretation: success/moderate/poor
- ‚úÖ Next action determined (use OV mapping / refine / run BRCA-specific)
- ‚úÖ Coverage stats included

**Timeline**: 2 hours

---

### 5. **Run BRCA Biomarker Correlation Analysis** üî• **HIGH PRIORITY**

**Status**: ‚ö†Ô∏è **PENDING** - Run in parallel with #4  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGH** - Identifies BRCA-specific pathways

**What**: Identify BRCA-specific diamond features for recurrence (proliferation, DDR, immune)

**Deliverable**:
- File: `scripts/sae/identify_brca_pathway_diamonds.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/brca_diamond_features.json`
- Pathways:
  - DDR (BRCA1, BRCA2, TP53, ATM, CHEK2)
  - Proliferation (MKI67, AURKA, BIRC5, CCNB1, MYBL2, STK15) - Full Oncotype DX
  - Immune (CD8A, PD-L1, CTLA4, LAG3)
- Results:
  ```json
  {
    "ddr_diamonds": [{"index": 1234, "cohens_d": 0.65, "p_value": 0.001}, ...],
    "proliferation_diamonds": [...],
    "immune_diamonds": [...]
  }
  ```

**Key Corrections** (from manager plan review):
- ‚úÖ Expanded proliferation gene list (full Oncotype DX 21-gene panel)
- ‚úÖ Added BRCA-specific DDR genes
- ‚úÖ Added immune genes for IO response

**Success Criteria**:
- ‚úÖ Proliferation diamonds: 5-10 features (Oncotype DX-relevant)
- ‚úÖ DDR diamonds: 3-7 features (may differ from OV)
- ‚úÖ Immune diamonds: 2-5 features
- ‚úÖ All features meet criteria: Cohen's d > 0.5, p < 0.05

**Timeline**: 8 hours (overnight)

---

### 6. **Compare Pathway Mappings** üî• **HIGH PRIORITY**

**Status**: ‚ö†Ô∏è **PENDING** - Depends on #4, #5  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGH** - Decision point for pathway selection

**What**: Compare OV DDR transfer vs BRCA-specific pathways

**Deliverable**:
- File: `scripts/sae/compare_pathway_mappings.py`
- Output: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/pathway_comparison.json`
- Results:
  ```json
  {
    "ov_ddr_auroc": 0.68,
    "brca_ddr_auroc": 0.72,
    "brca_proliferation_auroc": 0.74,
    "brca_immune_auroc": 0.63,
    "best_single_pathway": "proliferation",
    "recommendation": "use_brca_proliferation"
  }
  ```

**Success Criteria**:
- ‚úÖ AUROC computed for each pathway
- ‚úÖ Best single pathway identified
- ‚úÖ Recommendation made (use OV DDR / BRCA DDR / BRCA proliferation / multi-pathway)

**Timeline**: 2 hours

---

### 7. **Build Multi-Pathway Model** üî• **HIGH PRIORITY**

**Status**: ‚ö†Ô∏è **PENDING** - Depends on #6  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGH** - Final model for validation

**What**: Combine best pathways into composite model (DDR + proliferation)

**Deliverable**:
- File: `scripts/sae/build_brca_multipathway_model.py`
- Output: 
  - Model: `data/validation/sae_cohort/brca_sae_multipathway_model.pkl`
  - Results: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/brca_sae_validation_results.json`
- Results:
  ```json
  {
    "model_type": "multipathway",
    "sae_auroc": 0.78,
    "oncotype_dx_auroc": 0.65,
    "improvement": 0.13,
    "pathways_used": ["proliferation", "ddr"],
    "pathway_weights": {"proliferation": 0.6, "ddr": 0.4}
  }
  ```

**Success Criteria**:
- ‚úÖ Multi-pathway model trained
- ‚úÖ SAE AUROC ‚â• 0.75 (target)
- ‚úÖ Improvement vs Oncotype DX ‚â• +10 pp
- ‚úÖ Pathway weights optimized

**Timeline**: 4 hours

---

### 8. **Compute Oncotype DX Baseline** ‚ö†Ô∏è **IMPORTANT**

**Status**: ‚ö†Ô∏è **PENDING** - Required for comparison  
**Owner**: üü° **ZO (PARTIAL OWNERSHIP)** - May need help with Oncotype DX formula  
**Priority**: ‚ö†Ô∏è **MEDIUM** - Needed for validation comparison

**What**: Reproduce Oncotype DX 21-gene recurrence score for comparison

**Deliverable**:
- File: `scripts/sae/compute_oncotype_dx_baseline.py`
- Output: `data/validation/sae_cohort/brca_oncotype_dx_baseline.json`
- Method:
  - Extract 21-gene expression from TCGA-BRCA RNA-seq
  - Compute recurrence score (0-100) using Oncotype DX formula
  - Validate: Match published TCGA-BRCA Oncotype DX results (AUROC ~0.65)

**Success Criteria**:
- ‚úÖ Oncotype DX scores computed for 150+ patients
- ‚úÖ Baseline AUROC ~0.65 (validates reproduction)
- ‚úÖ Ready for comparison with SAE model

**Timeline**: 4 hours

---

### 9. **Create Validation Receipt** üî• **HIGH PRIORITY**

**Status**: ‚ö†Ô∏è **PENDING** - Final deliverable  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: üî• **HIGH** - Publication-ready validation report

**What**: Create publication-ready validation receipt

**Deliverable**:
- File: `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_VALIDATION_RECEIPT.md`
- Format:
  - JSON validation receipt (AUROC, 95% CI, improvement)
  - Markdown report (honest limitations, external validation needed)
  - Manuscript draft (ready for submission)
- Content:
  ```json
  {
    "sae_auroc": 0.78,
    "oncotype_dx_auroc": 0.65,
    "improvement": 0.13,
    "improvement_95_ci": [0.08, 0.18],
    "p_value": 0.001,
    "n_patients": 150
  }
  ```

**Success Criteria**:
- ‚úÖ Validation receipt complete (JSON + Markdown)
- ‚úÖ Statistical validation (bootstrap CI, permutation test)
- ‚úÖ Manuscript draft ready
- ‚úÖ Honest limitations documented

**Timeline**: 4 hours

---

### 10. **Update Bibliography & Execution Plan** ‚ö†Ô∏è **IMPORTANT**

**Status**: ‚ö†Ô∏è **PENDING** - Documentation update  
**Owner**: üéØ **ZO (FULL OWNERSHIP)**  
**Priority**: ‚ö†Ô∏è **MEDIUM** - Keep documentation current

**What**: Update SAE validation bibliography with BRCA results

**Deliverable**:
- Files:
  - `.cursor/MOAT/SAE_VALIDATION_BIBLIOGRAPHY.md` (updated)
  - `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/SAE_VALIDATION_EXECUTION_PLAN.md` (updated)
- Updates:
  - Mark Phase 1 (Breast) as ‚úÖ COMPLETE
  - Add validation receipt link
  - Update status table
  - Update publication roadmap

**Success Criteria**:
- ‚úÖ Bibliography updated with BRCA results
- ‚úÖ Execution plan marked complete
- ‚úÖ Status table updated
- ‚úÖ Publication roadmap updated

**Timeline**: 1 hour

---

## üìä PRIORITY RANKING

**CRITICAL BLOCKERS** (Must Do First):
1. Extract BRCA Recurrence Labels (#1) - Blocks all downstream
2. Verify DDR_bin Aggregation Method (#2) - Affects all pathway scoring
3. Check OV DDR Feature Coverage (#3) - May require re-extraction

**HIGH PRIORITY** (Core Validation):
4. Test OV DDR Transfer (#4) - Core hypothesis test
5. Run BRCA Biomarker Correlation (#5) - Identifies BRCA-specific pathways
6. Compare Pathway Mappings (#6) - Decision point
7. Build Multi-Pathway Model (#7) - Final model
9. Create Validation Receipt (#9) - Publication-ready

**MEDIUM PRIORITY** (Supporting):
8. Compute Oncotype DX Baseline (#8) - Needed for comparison
10. Update Bibliography (#10) - Documentation

---

## ‚è±Ô∏è TIMELINE

**Day 1 (Morning - 4 hours)**:
- ‚úÖ #1: Extract Recurrence Labels (4 hours)

**Day 1 (Afternoon - 2 hours)**:
- ‚úÖ #2: Verify DDR_bin Aggregation Method (2 hours)

**Day 1 (Evening - 2 hours)**:
- ‚úÖ #3: Check OV DDR Feature Coverage (2 hours)

**Day 1 (Overnight - 8 hours)**:
- ‚úÖ #5: Run BRCA Biomarker Correlation (8 hours) - PARALLEL

**Day 2 (Morning - 2 hours)**:
- ‚úÖ #4: Test OV DDR Transfer (2 hours)

**Day 2 (Afternoon - 2 hours)**:
- ‚úÖ #6: Compare Pathway Mappings (2 hours)

**Day 2 (Evening - 4 hours)**:
- ‚úÖ #7: Build Multi-Pathway Model (4 hours)

**Day 3 (Morning - 4 hours)**:
- ‚úÖ #8: Compute Oncotype DX Baseline (4 hours)

**Day 3 (Afternoon - 4 hours)**:
- ‚úÖ #9: Create Validation Receipt (4 hours)

**Day 3 (Evening - 1 hour**):
- ‚úÖ #10: Update Bibliography (1 hour)

**Total**: 2.5 days (with parallel execution)

---

## üéØ SUCCESS CRITERIA

**Overall Success**:
- ‚úÖ All 10 deliverables complete
- ‚úÖ BRCA SAE validation complete (SAE vs Oncotype DX)
- ‚úÖ Validation receipt ready (publication-ready)
- ‚úÖ Improvement ‚â• +10 pp (SAE AUROC 0.75+ vs Oncotype DX 0.65)

**Validation Success**:
- ‚úÖ SAE AUROC ‚â• 0.75 (target)
- ‚úÖ Improvement vs Oncotype DX ‚â• +10 pp
- ‚úÖ Statistical significance (p < 0.05)
- ‚úÖ Bootstrap 95% CI: Improvement > 0

**Publication Readiness**:
- ‚úÖ Validation receipt complete
- ‚úÖ Manuscript draft ready
- ‚úÖ Honest limitations documented
- ‚úÖ Ready for submission (JAMA Oncology target)

---

## üéØ OWNERSHIP & COMMITMENT

**What I'm Committing To Own**:

### ‚úÖ **FULL OWNERSHIP** (I will deliver these completely)

1. **Extract BRCA Recurrence Labels (#1)** - üî• CRITICAL
2. **Verify DDR_bin Aggregation Method (#2)** - üî• CRITICAL
3. **Check OV DDR Feature Coverage (#3)** - ‚ö†Ô∏è IMPORTANT
4. **Test OV DDR Transfer (#4)** - üî• HIGH
5. **Run BRCA Biomarker Correlation (#5)** - üî• HIGH
6. **Compare Pathway Mappings (#6)** - üî• HIGH
7. **Build Multi-Pathway Model (#7)** - üî• HIGH
9. **Create Validation Receipt (#9)** - üî• HIGH
10. **Update Bibliography (#10)** - ‚ö†Ô∏è MEDIUM

### üü° **PARTIAL OWNERSHIP** (May need help)

8. **Compute Oncotype DX Baseline (#8)** - May need help with Oncotype DX formula

**Total Commitment**:
- **Full ownership**: 9 deliverables (2.5 days)
- **Partial ownership**: 1 deliverable (may need help)

---

## üíÄ BRUTAL HONESTY

**What We Have**:
- ‚úÖ BRCA checkpoint: 200 patients, 6,465 variants, SAE features extracted
- ‚úÖ OV DDR mapping: 9 diamond features validated (AUROC 0.783)
- ‚úÖ Manager plan: Reviewed and corrected (4 issues fixed)

**What We Need**:
- ‚ö†Ô∏è Recurrence labels (blocking)
- ‚ö†Ô∏è DDR_bin aggregation method verified (critical)
- ‚ö†Ô∏è Feature coverage checked (may require re-extraction)

**What I'm NOT Promising**:
- ‚ùå Perfect transfer (OV DDR may not work for BRCA)
- ‚ùå Guaranteed improvement (may need BRCA-specific pathways)
- ‚ùå Publication-ready immediately (need validation first)

**What I AM Promising**:
- ‚úÖ Actually test OV DDR transfer
- ‚úÖ Identify BRCA-specific pathways if needed
- ‚úÖ Build best model (single or multi-pathway)
- ‚úÖ Validate vs Oncotype DX honestly
- ‚úÖ Document what works vs. what doesn't

---

## üîó RELATED FILES

**Execution Plans**:
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/SAE_VALIDATION_EXECUTION_PLAN.md`
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_PATHWAY_MAPPING_STRATEGY.md`
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_SAE_MANAGER_PLAN_REVIEW.md`

**Status Reports**:
- `.cursor/MOAT/SAE_INTELLIGENCE/BRCA_VALIDATION/BRCA_CHECKPOINT_STATUS.md`

**Audit & Bibliography**:
- `.cursor/MOAT/SAE_EXTRACTION_AUDIT_AZ.md`
- `.cursor/MOAT/SAE_VALIDATION_BIBLIOGRAPHY.md`

---

*Document Author: Zo (SAE BRCA Validation Agent)*  
*Last Updated: January 29, 2025*  
*Status: üöß IN PROGRESS - Planning complete, execution ready*

**Next Immediate Action**: Extract BRCA recurrence labels (#1) - 4 hours
